SCHEMBL3815434

SCHEMBL3815434

CON(C)C(=O)c1csc(NC(=O)[C@@H](N)Cc2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
TP53 P04637 1/20 0.44
MAPK1 P28482 1/20 0.44
CTSC P53634 1/20 0.42
MAPT P10636 2/20 0.42
POLB P06746 2/20 0.42
GAA P10253 1/20 0.42
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALPI P09923 1/20 0.40
PKM P14618 1/20 0.40
PTGS1 P23219 1/20 0.40
XIAP P98170 1/20 0.40
SLC7A5 Q01650 1/20 0.40
MME P08473 2/20 0.39
SLC15A1 P46059 1/20 0.39
AAK1 Q2M2I8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3813895 0.86 NPC1 (0.49) L3MBTL1TP53MAPK1CTSCGAA
SCHEMBL3816209 0.86 NPC1 (0.49) L3MBTL1TP53MAPK1CTSCGAA
SCHEMBL3813898 0.86 NPC1 (0.49) L3MBTL1TP53MAPK1CTSCGAA
SCHEMBL28767638 0.83 L3MBTL1 (0.54) L3MBTL1TP53MAPK1CTSCPOLB
SCHEMBL27677789 0.83 L3MBTL1 (0.54) L3MBTL1TP53MAPK1CTSCPOLB
SCHEMBL3817488 0.83 L3MBTL1 (0.54) L3MBTL1TP53MAPK1CTSCPOLB
SCHEMBL3815427 0.81 TP53 (0.44) L3MBTL1TP53MAPK1CTSCMAPT
SCHEMBL11325003 0.79 MAPK1 (0.67) L3MBTL1TP53MAPK1CTSCMAPT
Bromide SCHEMBL11323260 0.78 MAPK1 (0.66) L3MBTL1TP53MAPK1CTSCMAPT
SCHEMBL16638093 0.77 L3MBTL1 (0.49) L3MBTL1MAPK1MAPTPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791837-B1 SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2009-08-19 EP disclosed
US-7371869-B2 Substituted hydantoins HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1791837-A1 SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER F. Hoffmann-Roche AG (CH) 2007-06-06 EP disclosed
WO-2006029862-A1 SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2006-03-23 WO disclosed
US-20060063814-A1 Substituted hydantoins GOODNOW ROBERT A JR 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063814-A1 Substituted hydantoins HNMT, MAPK6, KYNU L3MBTL1 3534/4885TP53 913/4885MAPK1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.